Securing the Future of ADCs as Standard of Care Therapies by Unlocking Novel Payload Mechanisms to Combat Topo1 Resistance, Improving Translation of Efficacious and Tolerable ADCs to the Clinic

Venue details: Excel London, Royal Victoria Dock, 1 Western Gateway, London, England, E16 1XL, United Kingdom

Prices: GBP 2319.00 to GBP 6475.00

Time: 08:00 to 17:00

Speakers: Ali Warbington, Director, Toxicology, AbbVie, Ronnie Yeager, Research Fellow, Emerging Therapeutic Platforms, AbbVie, Shilpen Patel, Executive Medical Director, Oncology, and Global Development Lead, AbbVie, and more